Losartan Potassium Tablet, Film Coated
Product Images NDC 50090-7795

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 50090-7795). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907795)

Losartan Potassium 25 mg film-coated tablets carton by A-S Medication Solutions. Label shows USP grade Losartan Potassium, instructions to store at 68 to 77 degrees Fahrenheit, protect from light, and contains 90 tablets. The label also notes each film-coated tablet contains 25 mg Losartan Potassium.*

FDA Label Image

Losartanpotassiumfigure1 (Losartanpotassiumfigure1)

A line graph comparing the percentage of patients with primary endpoints over study months for Atenolol and Losartan Potassium. The x-axis represents Study Month (0 to 66), and the y-axis shows the percentage of patients with primary endpoints (0 to 16%). The graph indicates an adjusted risk reduction of 13% with a p-value of 0.021 for Losartan Potassium compared to Atenolol.*

FDA Label Image

Losartanpotassiumfigure2 (Losartanpotassiumfigure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over months of study for Atenolol and Losartan potassium. The x-axis shows study months from 0 to 66, and the y-axis shows the percentage of affected patients from 0 to 8%. The graph indicates a lower percentage for Losartan potassium versus Atenolol, with an annotation stating an adjusted risk reduction of 25%, p = 0.001.*

FDA Label Image

Losartanpotassiumfigure3 (Losartanpotassiumfigure3)

A forest plot chart comparing Losartan Potassium and Atenolol event rates for Primary Composite and Stroke (Fatal/Non-Fatal) outcomes across various patient subgroups, including age, gender, race, ISH, diabetes, and history of cardiovascular disease. The chart shows hazard ratios with 95% confidence intervals indicating relative event risks between the two treatments.*

FDA Label Image

Losartanpotassiumfigure4 (Losartanpotassiumfigure4)

A line graph comparing the percentage of patients with an event over 48 months for Losartan Potassium versus placebo. The x-axis represents months, and the y-axis shows the percentage of patients with the event, ranging from 0 to 60%. The graph indicates a risk reduction of 16.1% with Losartan Potassium compared to placebo, accompanied by a p-value of 0.022.*

FDA Label Image

Losartanpotassiumstructure (Losartanpotassiumstructure)

Chemical structure diagram of Losartan Potassium showing its molecular framework including rings, chlorine, hydroxyl group, and potassium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.